Abstract
In the search for antidepressant agents with a rapid onset of action, we have found that compound BIMT 17 (1-[2-[4-(3-trifluoromethylphenyl)piperazin-1- yl]ethyl]benzimidazol-[1H]-2-one) shows a good affinity for cerebral cortical 5-HT1A (pKi = 7.72) and 5-HT2A (pKi = 6.90) receptors, with no appreciable affinity for the other 5-HT receptor subtypes, including 5-HT2C. BIMT 17 reduced forskolin-stimulated cAMP accumulation in the cerebral cortex (pEC50 = 6.09) and in the hippocampus (pEC50 = 6.50), and antagonized 5-HT-induced phosphatidylinositol turnover (pKi = 6.96) in the cerebral cortex. The effect on cAMP accumulation was blocked by the 5-HT1A receptor antagonist tertatolol. Buspirone, 8-OH-DPAT and S 14671 (1-[2-(2-thenoylamino)ethyl]- 4[1-(7-methoxynaphtyl)]-piperazine), claimed to be 5-HT1A receptor agonists, did not reduce forskolin-stimulated cAMP formation in the cerebral cortex. On the basis of these data, it was concluded that BIMT 17 was the only compound that behaved as a full agonist with respect to the cAMP response in the cortex, while exerting concurrent agonism at 5-HT1A receptors and antagonism at 5-HT2A receptors. These characteristics might explain the peculiar behavior of BIMT 17 in mimicking the inhibit...Continue Reading
Citations
May 3, 2007·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Jesper EkelundMarc Laruelle
Jan 5, 2002·European Journal of Pharmacology·F Borsini, R Cesana
Apr 16, 1998·European Journal of Pharmacology·P D'AquilaP Willner
Jan 26, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·A BrambillaF Borsini
May 30, 2001·Bioorganic & Medicinal Chemistry·F BerardiV Tortorella
Apr 3, 1999·British Journal of Pharmacology·L E Rueter, P Blier
Nov 19, 2013·Pharmacology, Biochemistry, and Behavior·Lynda Uphouse
Feb 3, 2016·The Journal of Sexual Medicine·Matthew F LazenkaS Stevens Negus
Feb 7, 2012·The Journal of Sexual Medicine·Yves AubertDavid H Abbott
Feb 2, 2010·Social Science & Medicine·Annemarie Jutel
Nov 2, 2005·The Journal of Pharmacy and Pharmacology·Roberto PerroneVincenzo Tortorella
Aug 2, 2003·British Journal of Pharmacology·Roberto William InvernizziRosario Samanin
Feb 3, 2006·The Journal of Pharmacy and Pharmacology·Marcello LeopoldoRoberto Perrone
Nov 18, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Llorenç Díaz-MataixPau Celada
Mar 7, 2006·Brain Research·Małgorzata FilipKjell Fuxe
Jun 26, 2012·Psychoneuroendocrinology·Yves AubertDavid H Abbott
Mar 10, 2004·The Journal of Pharmacy and Pharmacology·Marcello LeopoldoVincenzo Tortorella
Jul 3, 2007·Neurochemistry International·Gino GiannacciniAntonio Lucacchini
Jul 23, 2016·PloS One·Aaron S CoynerMark E Pennesi